CD4 and adenocarcinoma: We next investigated TILs before and after different chemotherapy regimens and showed that the alterations in TILs were mostly independent of treatment regimen and pathological type, except for CD4+CD127+ T cells, which were slightly higher in pemetrexed-treated patients (adenocarcinoma) than in paclitaxel-treated patients (squamous cell carcinoma) in the NAC group (P = 0.0116; Supplementary Table 6–7).